No­vavax and Gavi set­tle over Covid-19 vac­cine part­ner­ship dis­pute 

No­vavax and Gavi, the Vac­cine Al­liance, have reached a set­tle­ment on their part­ner­ship dis­agree­ment, with the vac­cine man­u­fac­tur­er hand­ing Gavi a to­tal of $400 mil­lion through De­cem­ber 2028.

In the set­tle­ment, No­vavax has agreed to pay $75 mil­lion to Gavi and will al­so make sub­se­quent pay­ments of $80 mil­lion each year through the end of 2028. These pay­ments are due quar­ter­ly.

There is the op­tion of a year­ly “vac­cine cred­it” worth $80 mil­lion, where No­vavax’s an­nu­al pay­ments can be re­duced if Gavi ac­cess­es any of No­vavax’s Gavi-fund­ed vac­cines for use in low-in­come and low­er-mid­dle-in­come ter­ri­to­ries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.